Literature DB >> 9932718

Peroxynitrite-mediated attenuation of alpha- and beta-adrenoceptor agonist-induced vascular responses in vivo.

N A Benkusky1, S J Lewis, N W Kooy.   

Abstract

Peroxynitrite is produced by vascular endothelial and smooth muscle cells in response to inflammation, induces vascular relaxation, and alters vascular responses to endothelial-derived relaxing factors. The present study examined the changes in mean arterial pressure and hindquarter, renal, and mesenteric vascular resistances produced by the systemic administration of (i) the catecholamines epinephrine or norepinephrine, (ii) the alpha1-adrenoceptor agonist phenylephrine, (iii) the beta-adrenoceptor agonist isoproterenol or (iv) [Arg delta] vasopressin in pentobarbital-anesthetized rats prior to and following the systemic administration of peroxynitrite. The systemic administration of peroxynitrite significantly inhibited (i) epinephrine-induced pressor and renal and mesenteric vasoconstrictor responses, (ii) norepinephrine-induced pressor and hindquarter, renal, and mesenteric vasoconstrictor responses, (iii) phenylephrine-induced hindquarter and mesenteric vasoconstrictor responses, and (iv) isoproterenol-induced depressor and hindquarter and renal vasodilator responses. In comparison, the systemic administration of peroxynitrite had no effect on arginine vasopressin-induced pressor or vasoconstrictor responses. These results demonstrate selective and consequential attenuation of the hemodynamic effects produced by alpha- and beta-adrenoceptor agonists, suggesting that selective impairment of adrenoceptors by peroxynitrite may play a critical role in the hemodynamic dysfunction associated with inflammatory conditions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9932718     DOI: 10.1016/s0014-2999(98)00791-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

1.  Nitric oxide inhibits isoproterenol-stimulated adipocyte lipolysis through oxidative inactivation of the beta-agonist.

Authors:  P Klatt; J Cacho; M D Crespo; E Herrera; P Ramos
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

2.  Antioxidant therapy in sepsis.

Authors:  Gerd Albuszies; Uwe Bernd Brückner
Journal:  Intensive Care Med       Date:  2003-08-16       Impact factor: 17.440

3.  Cardiovascular effects of felypressin.

Authors:  Rodrigo Cecanho; Laurival Antonio De Luca; José Ranali
Journal:  Anesth Prog       Date:  2006

Review 4.  Pathophysiological roles of peroxynitrite in circulatory shock.

Authors:  Csaba Szabó; Katalin Módis
Journal:  Shock       Date:  2010-09       Impact factor: 3.454

5.  Neuronal nitric oxide synthase generates superoxide from the oxygenase domain.

Authors:  H Yoneyama; A Yamamoto; H Kosaka
Journal:  Biochem J       Date:  2001-11-15       Impact factor: 3.857

Review 6.  Nitric oxide and peroxynitrite in health and disease.

Authors:  Pál Pacher; Joseph S Beckman; Lucas Liaudet
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

Review 7.  Oxidative stress in the placenta.

Authors:  Leslie Myatt; Xiaolan Cui
Journal:  Histochem Cell Biol       Date:  2004-07-10       Impact factor: 4.304

8.  Co-activation of μ- and δ-opioid receptors elicits tolerance to morphine-induced ventilatory depression via generation of peroxynitrite.

Authors:  Alex P Young; Ryan B Gruber; Joe F Discala; Walter J May; Dylan McLaughlin; Lisa A Palmer; Stephen J Lewis
Journal:  Respir Physiol Neurobiol       Date:  2013-03-05       Impact factor: 1.931

9.  L-beta,beta-dimethylcysteine attenuates the haemodynamic responses elicited by systemic injections of peroxynitrite in anaesthetized rats.

Authors:  Jonathan E Graves; Neil W Kooy; Stephen J Lewis
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

10.  Role of free radicals in vascular dysfunction induced by high tidal volume ventilation.

Authors:  Leticia Martínez-Caro; José A Lorente; Judith Marín-Corral; Carolina Sánchez-Rodríguez; Alberto Sánchez-Ferrer; Nicolás Nin; Antonio Ferruelo; Marta de Paula; Pilar Fernández-Segoviano; Esther Barreiro; Andrés Esteban
Journal:  Intensive Care Med       Date:  2009-04-10       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.